Targeting CCR2(+) macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer

PURPOSE: Tumor-associated macrophages (TAMs) are known to contribute to adaptive resistance to anti-vascular endothelial growth factor (VEGF) antibody (AVA) therapy in ovarian cancer. BET (bromodomain and extra-terminal domain) inhibitors (BETi) may have unique roles in targeting TAMs. Our objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yutuan, Jennings, Nicholas B., Sun, Yunjie, Dasari, Santosh K., Bayraktar, Emine, Corvigno, Sara, Stur, Elaine, Glassman, Deanna, Mangala, Lingegowda S., Lankenau Ahumada, Adrian, Westin, Shannon N., Sood, Anil K., Hu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930900/
https://www.ncbi.nlm.nih.gov/pubmed/35094142
http://dx.doi.org/10.1007/s00432-021-03885-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930900/
https://www.ncbi.nlm.nih.gov/pubmed/35094142
http://dx.doi.org/10.1007/s00432-021-03885-z

Ejemplares similares